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SPRY domain- and SOCS box-containing proteins SPSB1, SPSB2, and SPSB4 interact with 
inducible nitric oxide synthase (iNOS), causing the iNOS to be polyubiquitinated and targeted 
for degradation. Inhibition of this interaction increases iNOS levels, and consequently cellular 
nitric oxide (NO) concentrations, and has been proposed as a potential strategy for killing 
intracellular pathogens. We previously described two DINNN-containing cyclic peptides (CP1 
and CP2) as potent inhibitors of the murine SPSB-iNOS interaction. In this study, we report 
the crystal structures of human SPSB4 bound to CP1 and CP2 and human SPSB2 bound to 
CP2. We then used these structures to design a new inhibitor in which an intramolecular 
hydrogen bond was replaced with a hydrocarbon linkage to form a smaller macrocycle while 
maintaining the bound geometry of CP2 observed in the crystal structures. This resulting 
pentapeptide SPSB-iNOS inhibitor (CP3) has a reduced macrocycle ring size, fewer 
nonbinding residues, and includes additional conformational constraints. CP3 has a greater 
affinity for SBSB2 ( KD = 7 nM as determined by surface plasmon resonance) and strongly 
inhibits the SPSB2-iNOS interaction in macrophage cell lysates. We have also determined the 
crystal structure of CP3 in complex with human SPSB2, which reveals the structural basis for 
the increased potency of CP3 and validates the original design. 
